Program
Amlodipine
Also written as “amlodipine”, “Amlodipine 5 mg” and “Amlodipine 10 mg”.
Its studies are mostly in Hypertension · Essential Hypertension · Hyperlipidemias · Kidney Diseases · Hypercholesterolemia, led by 35 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Novartis | 570 open or running | phase 4since Aug 25, 2005 | Aug 25, 2005 | none ahead |
| Boehringer Ingelheim | 220 open or running | phase 4since Oct 14, 2005 | Oct 14, 2005 | none ahead |
| Viatris | 130 open or running | phase 4since Aug 31, 2005 | Aug 31, 2005 | none ahead |
| Hanmi Pharmaceutical | 110 open or running | phase 3since Jul 14, 2009 | Jul 14, 2009 | none ahead |
| Dr. Reddy's Laboratories | 80 open or running | phase 1since May 26, 2010 | May 26, 2010 | none ahead |
| HK inno.N | 50 open or running | phase 3since Feb 16, 2015 | Feb 10, 2014 | none ahead |
| Handok | 40 open or running | phase 3since Jul 24, 2022 | Jul 21, 2020 | none ahead |
| Teva Pharmaceutical Industries | 40 open or running | phase 1since Feb 9, 2009 | Feb 9, 2009 | none ahead |
| Yuhan | 41 open or running | phase 4since Sep 4, 2023 | May 29, 2014 | none ahead |
| Chong Kun Dang Pharmaceutical | 30 open or running | phase 3since Jan 8, 2016 | Feb 14, 2014 | none ahead |
| Daewoong Pharmaceutical | 30 open or running | phase 3since Dec 12, 2016 | Mar 4, 2013 | none ahead |
| IlDong Pharmaceutical | 30 open or running | phase 3since Apr 11, 2016 | Mar 31, 2016 | none ahead |
| Merck | 30 open or running | phase 3since Feb 22, 2011 | Nov 10, 2008 | none ahead |
| Daewon Pharmaceutical | 20 open or running | phase 3since Oct 12, 2016 | Oct 12, 2016 | none ahead |
| Hikma Pharmaceuticals | 20 open or running | no phasesince Jan 15, 2008 | Jan 15, 2008 | none ahead |
| Jeil Pharmaceutical | 20 open or running | phase 1since Mar 9, 2015 | Mar 9, 2015 | none ahead |
| Menarini Group | 20 open or running | phase 4since Mar 4, 2022 | Mar 4, 2022 | none ahead |
| midas-pharma-gmbh | 20 open or running | phase 1since Jan 23, 2020 | Jan 23, 2020 | none ahead |
| Sun Pharmaceutical Industries | 20 open or running | no phasesince Oct 16, 2008 | Oct 16, 2008 | none ahead |
| Torrent Pharmaceuticals | 20 open or running | phase 1since Jul 1, 2009 | Jul 1, 2009 | none ahead |
| tsh-biopharm-corporation-limited | 20 open or running | phase 4since Jun 15, 2011 | Jun 15, 2011 | none ahead |
| bright-future-pharmaceuticals-factory-o-b-bright-future-phar | 10 open or running | phase 1since Mar 10, 2016 | Mar 10, 2016 | none ahead |
| Celltrion | 10 open or running | phase 3since Apr 27, 2026 | Apr 27, 2026 | none ahead |
| Genuine Research Center, Egypt | 10 open or running | phase 1since Jul 30, 2015 | Jul 30, 2015 | none ahead |
| hyundai-pharm | 11 open or running | phase 3since Oct 15, 2024 | Oct 15, 2024 | none ahead |
| invasc-therapeutics-inc | 10 open or running | phase 4since Jan 5, 2011 | Jan 5, 2011 | none ahead |
| kitov-pharmaceuticals-ltd | 10 open or running | phase 3since Jun 20, 2014 | Jun 20, 2014 | none ahead |
| Lotus Pharmaceutical | 10 open or running | phase 1since May 23, 2016 | May 23, 2016 | none ahead |
| Organon | 10 open or running | phase 4since Aug 30, 2005 | Aug 30, 2005 | none ahead |
| Pfizer | 10 open or running | phase 3since Mar 2, 2007 | Mar 2, 2007 | none ahead |
| servier | 10 open or running | phase 3since Feb 25, 2022 | Feb 25, 2022 | none ahead |
| shanghai-haini-pharmaceutical-co-ltd | 10 open or running | phase 1since Nov 17, 2016 | Nov 17, 2016 | none ahead |
| Shin Poong Pharmaceutical | 10 open or running | phase 2since Oct 24, 2016 | Oct 24, 2016 | none ahead |
| Takeda | 10 open or running | phase 3since Nov 17, 2016 | Nov 17, 2016 | none ahead |
| zentiva-k-s | 11 open or running | phase 3since May 25, 2026 | May 25, 2026 | Dec 31, 2027phase 3 · NCT07618806 |
Also a collaborator on its studies: CSPC Pharmaceutical Group and integrium.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
Before these, 46 studies since Feb 22, 2011.
- Nov 7, 2019Phase 3 study in HypercholesterolemiaYuhan · NCT04158076 · 131 enrolled · Korea, Republic of
- Jan 23, 2020midas-pharma-gmbh's first study: phase 1 study in Healthy VolunteersNew to midas-pharma-gmbhmidas-pharma-gmbh · NCT04245046 · 18 enrolled · Jordan
- Feb 7, 2020Phase 1 study in Healthy Volunteersmidas-pharma-gmbh · NCT04262765 · 18 enrolled · Jordan
- Jul 21, 2020Handok's first study: phase 2 study in Essential HypertensionNew to HandokHandok · NCT04488978 · 440 enrolled · Korea, Republic of
- Feb 25, 2022servier's first study: phase 3 study in Essential HypertensionNew to servierservier · NCT05288400 · 150 enrolled · Russian Federation
- Mar 4, 2022Menarini Group's first study: phase 4 study in HypertensionNew to Menarini GroupMenarini Group · NCT05279807 · 277 enrolled · Hungary
- Jul 24, 2022Phase 3 study in Essential HypertensionHandok · NCT05475665 · 157 enrolled · Korea, Republic of
- Aug 22, 2022Phase 4 study in HypertensionMenarini Group · NCT05513937 · 301 enrolled · Bulgaria
- Dec 14, 2022Phase 1 study in Healthy VolunteersHandok · NCT05663073 · 46 enrolled · Korea, Republic of
- Jan 8, 2023Phase 1 study in Healthy VolunteersHandok · NCT05688085 · 44 enrolled · Korea, Republic of
- Sep 4, 2023Phase 4 study in Essential HypertensionYuhan · NCT06041529 · 198 enrolled · South Korea
- Oct 15, 2024hyundai-pharm's first study: phase 3 study in HypertensionNew to hyundai-pharmhyundai-pharm · NCT06646354 · 125 planned · Korea, Republic of
- Apr 27, 2026Celltrion's first study: phase 3 study in HypertensionNew to CelltrionCelltrion · NCT07564726 · 163 enrolled · South Korea
- May 25, 2026zentiva-k-s's first study: phase 3 study in HypertensionNew to zentiva-k-szentiva-k-s · NCT07618806 · 344 planned
Ahead
- Dec 31, 2027Primary completion: phase 3 study in Hypertensionzentiva-k-s · NCT07618806
TargetBeta
“Voltage-gated L-type calcium channel blocker; Voltage-gated L-type calcium channel blocker; Voltage-gated L-type calcium channel blocker”ChEMBL 37, by rule
Other programs on the same 4 targets
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| Pregabalinrule | Viatris | phase 4 | 149 |
| Gabapentinrule | Viatris | phase 4 | 49 |
| Dronedaronerule | Sanofi | phase 4 | 18 |
| Nifedipinerule | Bayer | phase 4 | 18 |
Studies
The newest 60 of 170 led by companies developing it. Each opens its study page. Every study on its drug page →
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT07618806Hypertension | 3 | Not yet recruiting | zentiva-k-s | Dec 31, 2027 | 344 |
| NCT07564726Hypertension · South Korea | 3 | Completed | Celltrion | Feb 13, 2024 | 163 |
| NCT06646354Hypertension · Korea, Republic of | 3 | By invitation | hyundai-pharm | May 19, 2025 | 125 |
| NCT06041529Essential Hypertension · South Korea | 4 | Active, not recruiting | Yuhan | Feb 28, 2026 | 198 |
| NCT05688085Healthy Volunteers · Korea, Republic of | 1 | Completed | Handok | Dec 29, 2022 | 44 |
| NCT05663073Healthy Volunteers · Korea, Republic of | 1 | Completed | Handok | Dec 15, 2022 | 46 |
| NCT05513937Hypertension · Bulgaria | 4 | Completed | Menarini Group | Nov 15, 2022 | 301 |
| NCT05475665Essential Hypertension · Korea, Republic of | 3 | Completed | Handok | Mar 30, 2023 | 157 |
| NCT05279807Hypertension · Hungary | 4 | Completed | Menarini Group | Apr 28, 2022 | 277 |
| NCT05288400Essential Hypertension · Russian Federation | 3 | Completed | servier | Dec 18, 2018 | 150 |
| NCT04488978Essential Hypertension · Korea, Republic of | 2 | Completed | Handok | Nov 9, 2021 | 440 |
| NCT04262765Healthy Volunteers · Jordan | 1 | Completed | midas-pharma-gmbh | Mar 26, 2019 | 18 |
| NCT04245046Healthy Volunteers · Jordan | 1 | Completed | midas-pharma-gmbh | Feb 18, 2019 | 18 |
| NCT04161001Hypertension · Korea, Republic of | 3 | UNKNOWN | Daewoong Pharmaceutical | Nov 20, 2021 | 237 |
| NCT04158076Hypercholesterolemia · Korea, Republic of | 3 | Completed | Yuhan | Jan 14, 2021 | 131 |
| NCT04322266Healthy · Korea, Republic of | 1 | Completed | Hanmi Pharmaceutical | Feb 13, 2019 | 61 |
| NCT04081844Healthy · Korea, Republic of | 1 | Completed | Hanmi Pharmaceutical | Jun 28, 2018 | 31 |
| NCT03639480Hypertension · Korea, Republic of | 3 | UNKNOWN | HK inno.N | Oct 2018 | 180 |
| NCT03566316Hypertension With Hyperlipidemia · Korea, Republic of | 3 | Completed | IlDong Pharmaceutical | Jun 16, 2017 | 134 |
| NCT03461081Hypertension With Hyperlipidemia · Korea, Republic of | 1 | Completed | Jeil Pharmaceutical | Jul 12, 2017 | 32 |
| NCT03536598Hypertension With Hyperlipidemia | 3 | Completed | HK inno.N | Sep 4, 2017 | 203 |
| NCT03009487Hypertension · Korea, Republic of | 3 | Completed | Daewoong Pharmaceutical | Apr 2018 | 265 |
| NCT02974439Bioequivalence · China | 1 | Completed | shanghai-haini-pharmaceutical-co-ltd | Mar 21, 2017 | 60 |
| NCT02969265Hypertension · China | 3 | Withdrawn | Takeda | Jul 12, 2018 | 0 |
| NCT02944734Essential Hypertension · Korea, Republic of | 2 | Completed | Shin Poong Pharmaceutical | Dec 2015 | 392 |
| NCT03210532Hypertension · Korea, Republic of | 3 | Completed | Daewon Pharmaceutical | Sep 2017 | 129 |
| NCT02933658Hypertension | 1 | Completed | Daewon Pharmaceutical | Nov 2015 | 71 |
| NCT02899455Hypertension · Korea, Republic of | 3 | Completed | Hanmi Pharmaceutical | Jun 2016 | 146 |
| NCT02789475Hypertension · Korea, Republic of | 1 | UNKNOWN | Lotus Pharmaceutical | Jul 2016 | 38 |
| NCT02738632Essential Hypertension · Korea, Republic of | 3 | Completed | IlDong Pharmaceutical | Aug 2016 | 300 |
| NCT02739672Healthy · Korea, Republic of | 1 | Completed | IlDong Pharmaceutical | Apr 6, 2016 | 40 |
| NCT02707913Healthy | 1 | Completed | bright-future-pharmaceuticals-factory-o-b-bright-future-phar | Aug 2016 | 17 |
| NCT02651870Hypertension · Korea, Republic of | 3 | Completed | Chong Kun Dang Pharmaceutical | Feb 25, 2016 | 135 |
| NCT02519010Healthy · Egypt | 1 | Completed | Genuine Research Center, Egypt | Mar 2011 | 36 |
| NCT02387619Hypertension · Korea, Republic of | 1 | Completed | Jeil Pharmaceutical | Mar 2015 | 41 |
| NCT02368665Essential Hypertension · Korea, Republic of | 3 | Completed | HK inno.N | Nov 2015 | 180 |
| NCT02368652Essential Hypertension · Korea, Republic of | 3 | Completed | HK inno.N | Nov 2015 | 181 |
| NCT02387554Hypertension · Korea, Republic of | 1 | Completed | Hanmi Pharmaceutical | Oct 2014 | 33 |
| NCT02295046Healthy · Germany | 1 | Completed | Dr. Reddy's Laboratories | Oct 2011 | 80 |
| NCT02292069Healthy · India | 1 | Completed | Dr. Reddy's Laboratories | Sep 2011 | 90 |
| NCT02261064Healthy | 1 | Completed | Boehringer Ingelheim | Feb 2009 | 32 |
| NCT02259829Healthy | 1 | Completed | Boehringer Ingelheim | Nov 2007 | 84 |
| NCT02259816Healthy | 1 | Completed | Boehringer Ingelheim | Aug 2006 | 38 |
| NCT02233218Healthy Male Volunteer · Korea, Republic of | 1 | Completed | Yuhan | Oct 2014 | 60 |
| NCT02243319Healthy · Korea, Republic of | 1 | Completed | Hanmi Pharmaceutical | Dec 2014 | 24 |
| NCT02193308Healthy | 1 | Completed | Boehringer Ingelheim | Nov 2007 | 84 |
| NCT02183675Healthy · Japan | 1 | Completed | Boehringer Ingelheim | Oct 2014 | 36 |
| NCT02172040Hypertension · United Kingdom | 3 | Completed | kitov-pharmaceuticals-ltd | Nov 19, 2015 | 152 |
| NCT02206165Essential Hypertension · Korea, Republic of | 2 | UNKNOWN | Chong Kun Dang Pharmaceutical | Apr 2015 | 456 |
| NCT02152969Hypertension · Korea, Republic of | 1 | Completed | Yuhan | Aug 2014 | 66 |
| NCT02064556Hypertension · Korea, Republic of | 1 | Completed | Chong Kun Dang Pharmaceutical | Jul 2014 | 24 |
| NCT02062645Essential Hypertension · Turkey | 4 | Completed | Novartis | Sep 2015 | 115 |
| NCT02059616Essential Hypertension · Korea, Republic of | 2 | UNKNOWN | HK inno.N | Jun 2015 | 384 |
| NCT02058446Essential Hypertension · Taiwan | 4 | Completed | tsh-biopharm-corporation-limited | Mar 2014 | 36 |
| NCT01911780Hypertension · Japan | 3 | Completed | Boehringer Ingelheim | Jan 2015 | 132 |
| NCT01806311Hypertension · Korea, Republic of | 1 | Completed | Daewoong Pharmaceutical | Aug 2013 | 36 |
| NCT01506011Fasting · India | 1 | Completed | Dr. Reddy's Laboratories | Apr 2007 | 50 |
| NCT01505998Lecithin Cholesterol Acyltransferase Deficiency · India | 1 | Completed | Dr. Reddy's Laboratories | May 2007 | 49 |
| NCT01375322Hypertension · Taiwan | 4 | Completed | tsh-biopharm-corporation-limited | Jun 2010 | 226 |
| NCT01302691Hypertension | 3 | Completed | Merck | Apr 1, 2012 | 327 |
How it is read
Names in the registry
- “Amlodipine”, 44 entries
- “amlodipine”, 14 entries
- “Amlodipine 5 mg”, 9 entries
- “Amlodipine 10 mg”, 6 entries
- “valsartan + amlodipine”, 5 entries
Conditions, from the studies’ own filings
- Hypertension, 119 studies
- Essential Hypertension, 32 studies
- Hyperlipidemias, 3 studies
- Kidney Diseases, 1 study
- Hypercholesterolemia, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.